Asthma update: Part II. Medical management

American Family Physician

Volumn 70, Issue 6, 2004, Pages 1061-1066

  Mintz, Matthew ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NEDOCROMIL SODIUM; PLACEBO; SALMETEROL; THEOPHYLLINE; TRIAMCINOLONE; ZAFIRLUKAST;

ADRENAL SUPPRESSION; ADULT; ASTHMA; BONE DENSITY; BONE MINERAL; CATARACT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE CLASSIFICATION; DRUG CHOICE; DRUG MEGADOSE; DRUG SAFETY; DRY POWDER; FACE MASK; FORCED EXPIRATORY VOLUME; GLAUCOMA; GROWTH DISORDER; HUMAN; INFANT; LOW DRUG DOSE; LUNG FUNCTION; MAJOR CLINICAL STUDY; META ANALYSIS; METERED DOSE INHALER; NEBULIZER; PEAK EXPIRATORY FLOW; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ACETATES; ADRENERGIC BETA-AGONISTS; ANTI-BACTERIAL AGENTS; ASTHMA; CHILD; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; LEUKOTRIENE ANTAGONISTS; PRACTICE GUIDELINES; QUINOLINES; RESPIRATORY FUNCTION TESTS;

EID: 4644223180     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma: expert panel report 2. Bethesda, Md.: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, 1997; NIH publication no. 97-4051.
2. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma: update on selected topics-2002. Bethesda, Md.: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, 2003; NIH publication no. 02-5074.
3. Mintz M. Asthma update: Part I. Diagnosis, monitoring, and prevention of disease progression. Am Fam Physician 2004;70:893-8.
4. Kemp JP, Kemp JA. Management of asthma in children. [published erratum appears in Am Fam Physician 2002;65:386]. Am Fam Physician 2001;63:1341-8,1353- 4.
5. Kemp JP, Kemp JA. Management of asthma in children. [published erratum appears in Am Fam Physician 2002;65:386]. Am Fam Physician 2001;63:1341-8,1353- 4.
6. Taussig LM, Wright AL, Holberg HJ, Halonen M, Morgan WJ, Martinez FD. Tucson Children's Respiratory Study: 1980 to present. J Allergy Clin Immunol 2003;111:661-75.
7. Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997;277:887-91.
8. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000;343:332-6.
9. Busse W, Raphael GD, Galant S, Kalberg C, Goode-Sellers S, Srebro S, et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol 2001;107:461-8.
10. Ducharme F, Hicks G, Kakuma R. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2004;(1): CD003133.
11. Simons FE. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. N Engl J Med 1997;337:1659-65.
12. Allen DB, Bronsky EA, LaForce CF, Nathan RA, Tinkelman DG, Vandewalker ML, et al. Growth in asthmatic children treated with fluticasone propionate. Fluticasone Propionate Asthma Study Group. J Pediatr 1998;132(3 pt 1):472-7.
13. Shapiro G, Mendelson L, Kraemer MJ, Cruz-Rivera M, Walton-Bowen K, Smith JA. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immunol 1998;102:789-96.
14. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 2000;343:1054-63.
15. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000;343:1064-9.
16. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001;345:941-7.
17. Glazer JL. Bone loss and inhaled glucocorticoids. N Engl J Med 2002;346:533-5.
18. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994;344:219-24.
19. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-8.
20. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000;320:1368-73.
21. Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast [published erratum appears in J Allergy Clin Immunol 2001;107:614]. J Allergy Clin Immunol 2000;106:1088-95.
22. Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast [published erratum appears in J Allergy Clin Immunol 2001;107:614]. J Allergy Clin Immunol 2000;106:1088-95.
23. Ringdal N, Eliraz A, Pruzinec R, Weber HH, Mulder PG, Akveld M, et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 2003;97:234-41.
24. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial Am J Respir Crit Care Med 2001;164(8 pt 1):1392-7.
25. Johnson M. The preclinical pharmacology of salmeterol: bronchodilator effects. Eur Respir Rev 1991;1:253-6.
26. Lemanske RF Jr, Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy JV, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001;285:2594-603.
27. Mcivor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998;158:924-30.
28. Busse W, Koenig SM, Oppenheimer J, Sahn SA, Yancey SW, Reilly D, et al. Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily. J Allergy Clin Immunol 2003;111:57-65.
29. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathological outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999;159(4 pt 1):1043-51.
30. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group [published erratum appears in N Engl J Med 1998;338:139]. N Engl J Med 1997;337:1405-11.
31. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group [published erratum appears in N Engl J Med 1998;338:139]. N Engl J Med 1997;337:1405-11.
32. Stempel DA, O'Donnell JC, Meyer JW. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J Allergy Clin Immunol 2002;109:433-9.
33. Knobil K, Yancey S, Kral K, Rickard K. Salmeterol Multicenter Asthma Research Trial (SMART): results from an interim analysis [Abstract]. Chest 2003;124:335S.
34. Boudreaux ED, Emond SD, Clark S, Camargo CA Jr. Acute asthma among adults presenting to the emergency department: the role of race/ethnicity and socioeconomic status. Chest 2003;124:803-12.
35. Shapiro GG, Eggleston PA, Pierson WE, Ray CG, Bierman CW. Double-blind study of the effectiveness of a broad spectrum antibiotic in status asthmaticus. Pediatrics 1974;53:867-72.
36. Graham VA, Milton AF, Knowles GK, Davies RJ. Routine antibiotics in hospital management of acute asthma. Lancet 1982;1(8269):418-20.
37. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ 1993;307:982-6.
38. Johnston SL, Pattermore PK, Sanderson G, Smith S, Lampe F, Josephs L, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995;310:1225-9.